Table 3.
Comparison of clinicopathological features between right RCC with GADVR and left RCC with GADVR
| Right GADVR (n = 11) | Left GADVR (n = 10) | P | |
|---|---|---|---|
| Gender, n (%) | 0.635 | ||
| Male | 9 (81.8%) | 7 (70.0%) | |
| Female | 2 (18.2%) | 3 (30.0%) | |
| Age, y, mean ± SD | 55.09 ± 10.19 | 60.40 ± 6.69 | 0.179 |
| Clinical symptoms, n (%) | 1.000 | ||
| No | 0 (0%) | 1 (10.0%) | |
| Local symptoms | 8 (72.7%) | 8 (80.0%) | |
| Systemic symptoms | 1 (9.1%) | 0 (0%) | |
| Both | 2 (18.2%) | 1 (10.0%) | |
| BMI, kg/m2, mean ± SD | 25.18 ± 2.03 | 24.69 ± 3.32 | 0.687 |
| Surgical approach, n (%) | 0.635 | ||
| Laparoscope | 2 (18.2%) | 3 (30.0%) | |
| Open | 9 (81.8%) | 7 (70.0%) | |
| Mayo classification, n (%) | 0.430 | ||
| 0 | 0 (0%) | 2 (20.0%) | |
| 1 | 1 (9.1%) | 3 (20.0%) | |
| 2 | 7 (63.6%) | 12 (50.0%) | |
| 3 | 3 (27.3%) | 4 (10.0%) | |
| IVC segmental resection, n (%) | 0.080 | ||
| No | 2 (18.2%) | 6 (60.0%) | |
| Yes | 9 (81.8%) | 4 (40.0%) | |
| Preoperative serum creatinine, µmol/L, mean ± SD | 109.82 ± 20.89 | 99.40 ± 17.50 | 0.233 |
| Serum creatinine one week after operation, µmol/L, median (IQR) | 96.00 (45.00) | 97.50 (49.00) | 0.654 |
| Tumor diameter, cm, mean ± SD | 8.70 ± 2.77 | 8.12 ± 2.32 | 0.611 |
| Clinical N stage, n (%) | 0.311 | ||
| cN0 | 4 (36.4%) | 1 (10.0%) | |
| cN1 | 7 (63.6%) | 9 (90.0%) | |
| Adrenal metastasis, n (%) | 0.586 | ||
| No | 10 (90.9%) | 8 (80.0%) | |
| Yes | 1 (9.1%) | 2 (20.0%) | |
| Distant metastasis, n (%) | 0.035* | ||
| No | 11 (100%) | 6 (60.0%) | |
| Yes | 0 (0%) | 4 (40.0%) | |
| Bland thrombus, n (%) | 0.030* | ||
| No | 2 (18.2%) | 7 (70.0%) | |
| Yes | 9 (81.8%) | 3 (30.0%) | |
| Sarcomatoid feature, n (%) | 1.000 | ||
| No | 9 (81.8%) | 9 (90.0%) | |
| Yes | 2 (18.2%) | 1 (10.0%) | |
| Perirenal fat infiltration, n (%) | 1.000 | ||
| No | 8 (72.7%) | 7 (70.0%) | |
| Yes | 3 (27.3%) | 3 (30.0%) | |
| Pathology type, n (%) | 0.311 | ||
| Clear cell RCC | 10 (90.9%) | 7 (70.0%) | |
| Non‐clear cell RCC | 1 (9.1%) | 3 (30.0%) | |
| Nuclear grade, n (%) | 1.000 | ||
| 2 | 4 (36.4%) | 4 (40.0%) | |
| 3 | 6 (54.5%) | 5 (50.0%) | |
| 4 | 1 (9.1%) | 1 (10.0%) | |
| Lymph node dissection, n (%) | 1.000 | ||
| No | 6 (54.5%) | 6 (60.0%) | |
| Yes | 5 (45.5%) | 4 (40.0%) | |
| ASA grade, n (%) | 0.724 | ||
| 1 | 1 (9.1%) | 1 (10.0%) | |
| 2 | 8 (72.7%) | 9 (90.0%) | |
| 3 | 2 (18.2%) | 0 (0%) | |
| Operative time, min, mean ± SD | 338.18 ± 54.97 | 404.30 ± 125.70 | 0.150 |
| Surgical blood loss, mL, median (IQR) | 1500.00 (1100.00) | 1000.00 (650.00) | 0.085 |
| Postoperative complication, n (%) | 0.395 | ||
| No | 4 (36.4%) | 6 (60.0%) | |
| Yes | 7 (63.6%) | 4 (40.0%) | |
| Severe postoperative complication, n (%) | 1.000 | ||
| No | 10 (90.9%) | 9 (90.0%) | |
| Yes | 1 (9.1%) | 1 (10.0%) | |
| Thrombus adhering to the IVC, n (%) | 0.311 | ||
| No | 1 (9.1%) | 3 (30.0%) | |
| Yes | 10 (90.9%) | 7 (70.0%) | |
GADVR growing against the direction of venous return, BMI body mass index, SD standard deviation, IQR interquartile range, RCC renal cell carcinoma, ASA American Society of Anesthesiologists, IVC inferior vena cava
*p<0.05